STOK logo

Stoke Therapeutics, Inc. Common Stock


STOK: Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.


Show STOK Financials

Consumer Interest
SEC Filings

Recent trades of STOK by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by STOK's directors and management

Government lobbying spending instances

  • $30,000 Jan 19, 2023 Issue: Health Issues
  • $30,000 Oct 20, 2022 Issue: Health Issues
  • $30,000 Jul 19, 2022 Issue: Health Issues
  • $30,000 Apr 19, 2022 Issue: Health Issues
U.S. Patents

New patents grants

  • Patent Title: Antisense oligomers and uses thereof Aug. 24, 2021
  • Patent Title: Antisense oligomers for treatment of conditions and diseases Feb. 09, 2021
  • Patent Title: Antisense oligomers for treatment of conditions and diseases Jun. 16, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of STOK in WallStreetBets Daily Discussion


Recent insights relating to STOK

CNBC Recommendations

Recent picks made for STOK stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in STOK

Corporate Flights

Flights by private jets registered to STOK